Nilotinib
MW Deininger - Clinical cancer research, 2008 - AACR
Requests for reprints: Michael Deininger, Division of Hematology and Medical Oncology,
Oregon Health and Science University Cancer Institute, L592, 3181 Southwest Sam Jackson …
Oregon Health and Science University Cancer Institute, L592, 3181 Southwest Sam Jackson …
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations …
S Soverini, A Gnani, S Colarossi… - Blood, The Journal …, 2009 - ashpublications.org
Dasatinib and nilotinib are tyrosine kinase inhibitors (TKIs) developed to overcome imatinib
resistance in Philadelphia-positive leukemias. To assess how Bcr-Abl kinase domain …
resistance in Philadelphia-positive leukemias. To assess how Bcr-Abl kinase domain …
Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance
Multidrug resistance remains a significant obstacle to successful chemotherapy. The ability
to determine the possible resistance mechanisms and surmount the resistance is likely to …
to determine the possible resistance mechanisms and surmount the resistance is likely to …
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
NP Shah, BJ Skaggs, S Branford… - The Journal of …, 2007 - Am Soc Clin Investig
Molecularly targeted kinase inhibitor cancer therapies are currently administered
sequentially rather than simultaneously. We addressed the potential long-term impact of this …
sequentially rather than simultaneously. We addressed the potential long-term impact of this …
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
MS Zabriskie, NA Vellore, KC Gantz, MW Deininger… - Leukemia, 2015 - nature.com
Philadelphia chromosome-positive (Ph+) leukemia is driven by the constitutive enzymatic
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
Defining and managing imatinib resistance
MJ Mauro - ASH Education Program Book, 2006 - ashpublications.org
While imatinib is highly effective therapy, with improving prospects over time for sustained
remission and potential to severely limit or eliminate disease progression and …
remission and potential to severely limit or eliminate disease progression and …
[HTML][HTML] Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia …
P La Rosée, S Holm-Eriksen, H Konig, N Härtel… - …, 2008 - haematologica.org
Actual BCR-ABL kinase inhibition in vivo as determined by phospho-CRKL (pCRKL)
monitoring has been recognized as a prognostic parameter in patients with chronic …
monitoring has been recognized as a prognostic parameter in patients with chronic …
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
For patients with chronic myeloid leukemia in chronic phase (CMLCP), treatment with a BCR-
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia
OG Ottmann, RA Larson, HM Kantarjian, PD Le Coutre… - Leukemia, 2013 - nature.com
The t (9; 22)(q34; q11) translocation, known as the Philadelphia chromosome (Ph), is
present in B15–30% of adult patients with acute lymphoblastic leuremia (ALL). 1 This …
present in B15–30% of adult patients with acute lymphoblastic leuremia (ALL). 1 This …